REUTERS: The U.S. Food and Drug Administration on Friday approved AbbVie Inc's new treatment for rheumatoid arthritis, a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira faces competition.
The drug, Rinvoq, also called upadacitinib, was approved to treat rheumatoid arthritis, according to a notice from the FDA.(http://bit.ly/2KFUa5H)
(Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)